Heron Therapeutics Inc
Închisă
SectorSănătate
0.32 -3.03
Rezumat
Modificarea prețului
24h
Minim
0.31
Maxim
0.34
Venit | 2.6M -5.5M |
|---|---|
Vânzări | 3M 38M |
EPS | -0.03 |
Marjă de profit | -14.573 |
Angajați | 128 |
EBITDA | 2.1M -5.5M |
Următoarele câștiguri | 3 nov. 2026 |
|---|
Capitalizare de piață | -36M 61M |
|---|---|
Deschiderea anterioară | 3.35 |
Închiderea anterioară | 0.32 |
Sentimentul știrilor
By Acuity
46%
54%
148 / 340 Clasament în Healthcare
Heron Therapeutics Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Heron Therapeutics Inc Așteptări
Sentiment
By Acuity
148 / 340 Clasament în Sănătate
Sentimentul știrilor
Evidențe de creștere
Volatilitate
Sub medie
Volumul știrilor (RCV)
Peste medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Heron Therapeutics Inc
Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
